Concepedia

Stefan Zajic

SZ

19

Publications

880

Citations

13

H-Index

2000

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

The University of Texas MD Anderson Cancer Center

GlaxoSmithKline (United States)

Memorial Sloan Kettering Cancer Center

Washington University in St. Louis

Stefan Zajic is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, immune surveillance, and engineering.

ORCID

Top concepts

Publications per year

2000–2025

19

Publications

19

Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug–Drug Interaction Trial Design

Marc L. Reitman, Xiaoyan Chu, Xiaoxin Cai et al. · Clinical Pharmacology & Therapeutics · 2010 · 156 citations

Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies

S. Aubrey Stoch, Stefan Zajic, Julie A. Stone et al. · Clinical Pharmacology & Therapeutics · 2009 · 156 citations

Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases

Greg M. Thurber, Stefan Zajic, K. Dane Wittrup · Journal of Nuclear Medicine · 2007 · 133 citations · Full text

Odanacatib, a selective cathepsin <scp>K</scp> inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers

S. Aubrey Stoch, Stefan Zajic, Julie A. Stone et al. · British Journal of Clinical Pharmacology · 2012 · 77 citations · Full text

Influence of Residual Water on the Adsorption of Atmospheric Gases in Li−X Zeolite:  Experiment and Simulation

Nick D. Hutson, Stefan Zajic, Ralph T. Yang · Industrial & Engineering Chemistry Research · 2000 · 69 citations

, , +11

Rows per page

1–5 of 19